BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ:BMRN) to Outperform from Market Perform, and the price target remains at $102, noting its skewed risk/reward.
Friday, the FDA approved BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased